COMMUNIQUÉS West-GlobeNewswire

Alabama Attorney General Steve Marshall Champions The Helios Alliance's Project RenewAL to Advance Statewide Opioid Abatement
31/03/2026
Building on proven success in southwest Alabama, the partnership will assist cities and counties across the State in spending opioid settlement resources effectively — with local leadership, regional cooperation, and [...]
Berry Street Joins Amazon's Health Benefits Connector, Expanding Access to one of Healthcare's Most Underutilized Benefits
31/03/2026
Amazon customers can now discover and enroll in Berry Street's evidence-based nutrition care for weight loss, 30+ conditions NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Berry Street , an AI-powered nutrition therapy [...]
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31/03/2026
– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS [...]
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
31/03/2026
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth Initial patient dosed in the First-in-Human clinical trial of ADCX-020, marking Adcytherix’s [...]
ZymoChem's BAYSE™ Becomes First Bio-Based Superabsorbent to Match and Outperform Petroleum-Based Materials
31/03/2026
New research paper reveals breakthrough performance data and successful consumer trials for a biodegradable alternative to the plastics at the heart of billions of diapers, period products, and incontinence pads [...]
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., [...]
Vantive Presents New Data at WCN on How Coordinated Care Ecosystems Can Expand Home-Based Peritoneal Dialysis Access and Improve Patient Outcomes
31/03/2026
Nephroprotection and early intervention support more planned dialysis starts, improved patient outcomes and increased use of home therapies, according to new studies. Real-world studies also evaluate a unique care [...]
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
31/03/2026
Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3 2026 with first-in- [...]
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025
31/03/2026
PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services, and [...]
Global Medtech CDMO Market Grows to $96.5B in 2025 as Pharma-Medtech Convergence Emerges as a Defining Accelerator
31/03/2026
Alira Health’s annual CDMO medtech report highlights growth, consolidation, and capability expansion; market projected to reach $143.6B by 2030 at an 8.3% CAGR FRAMINGHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Alira [...]
Lighthouse Autism Center Opening New Autism Therapy Center in Rocky Mount, North Carolina
31/03/2026
ROCKY MOUNT, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Lighthouse Autism Center (LAC), a leading provider of center-based autism therapy, is proud to announce the opening of a new autism therapy center in Rocky Mount, [...]
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31/03/2026
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated [...]
EssilorLuxottica and Meta Expand AI Glasses Portfolio with Ray-Ban Meta Optics Styles
31/03/2026
EssilorLuxottica and Meta Expand AI Glasses Portfolio with Ray-Ban Meta Optics Styles Paris, France and Menlo Park, CA (31 March 2026) – EssilorLuxottica and Meta announce the expansion of their AI glasses portfolio [...]
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
31/03/2026
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over [...]
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
31/03/2026
TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrated safety, tolerability, and pharmacokinetics [...]
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
31/03/2026
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® FDA-approved in geographic [...]
American Shared Hospital Services Reports Fourth Quarter and Full Year 2025 Financial Results
31/03/2026
Announces Seven Year Extension of Proton Therapy Lease Agreement with Orlando Health Through 2033 Conference Call Scheduled for 12:00 PM ET Today SAN FRANCISCO, March 31, 2026 (GLOBE NEWSWIRE) -- American Shared [...]
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
31/03/2026
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® FDA-approved in geographic [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, [...]

Pages